Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.

导出 OA

翻译打印收藏纠错

作者： Xuqi,Sun ^[1] ; Jie,Mei ^[2] ; Wenping,Lin ^[3] ; Ziliang,Yang ^[1] ; Wei,Peng ^[2] ; Jinbin,Chen ^[1] ; Yaojun,Zhang ^[2] ; Li,Xu ^[1] ; Minshan,Chen ^[2]

作者单位： Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. ^[1] Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Dongfeng East Road 651, Guangzhou, 510060, China. ^[2] Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510060, China. ^[3] Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. xuli@sysucc.org.cn. ^[4] Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Dongfeng East Road 651, Guangzhou, 510060, China. xuli@sysucc.org.cn. ^[5] Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. chenmsh@sysucc.org.cn. ^[6] Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Dongfeng East Road 651, Guangzhou, 510060, China. chenmsh@sysucc.org.cn. ^[7]

关键词 AFP Hepatocellular carcinoma Immunotherapy PIVKA-II Survival